The standard of chemotherapy care in Nigeria for HER2-positive breast cancer is anthracycline (doxorubicin-epirubicin with cyclophosphamide with or without fluorouracil [AC-EC-FEC]) for 4 courses, followed by a taxane with trastuzumab. Here, ERBB2 is linked to breast carcinoma.